17
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found
      Is Open Access

      The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Inhibition of neutral endopeptidases (NEP) results in a beneficial increase in plasma concentrations of natriuretic peptides such as ANP. However NEP inhibitors were ineffective anti-hypertensives, probably because NEP also degrades vasoconstrictor peptides, including endothelin-1 (ET-1). Dual NEP and endothelin converting enzyme (ECE) inhibition may be more useful. The aim of the study was to determine whether SLV-306 (daglutril), a combined ECE/NEP inhibitor, reduced the systemic conversion of big ET-1 to the mature peptide. Secondly, to determine whether plasma ANP levels were increased.

          Related collections

          Author and article information

          Journal
          Life Sci.
          Life sciences
          1879-0631
          0024-3205
          Oct 15 2012
          : 91
          : 13-14
          Affiliations
          [1 ] British Heart Foundation Research Centre, University of Glasgow, UK.
          Article
          S0024-3205(12)00145-2
          10.1016/j.lfs.2012.03.022
          22480515
          Copyright © 2012 Elsevier Inc. All rights reserved.

          Comments

          Comment on this article